Comparative Pharmacology
Head-to-head clinical analysis: COMPAZINE versus PROLIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPAZINE versus PROLIXIN.
COMPAZINE vs PROLIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Fluphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system. It also exhibits alpha-adrenergic blocking activity and anticholinergic effects.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
Initial: 2.5-10 mg orally every 6-8 hours; maintenance: 1-5 mg orally every 6-8 hours. Maximum 40 mg/day. For deep IM: 2.5-10 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
Terminal half-life 14-24 hours; clinical context: allows once-daily or twice-daily dosing
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Primarily renal (70-80% as metabolites, <1% unchanged) and biliary/fecal (20-30%)
Category C
Category C
Antipsychotic (Phenothiazine) / Antiemetic
Antipsychotic (Phenothiazine)